In vivo imaging of renal redox status during azelnidipine treatment

Hypertension Research

Volumn 31, Issue 8, 2008, Pages 1643-1650

  Hirayama, Aki ^a   Ueda, Atsushi ^b   Oteki, Takaaki ^c   Nagase, Sohji ^d   Aoyagi, Kazumasa ^a   Koyama, Akio ^e  

^a TSUKUBA UNIVERSITY OF TECHNOLOGY   (Japan)

^b Namegata District General Hospital   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d Nagase Naika Clinic   (Japan)

^e IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

Azelnidipine; Electron paramagnetic resonance; Imaging; Oxidative stress

Indexed keywords

3 CARBAMOYL 2,2,5,5 TETRAMETHYL 3 PYRROLINE 1 OXYL; AZELNIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTRON SPIN RESONANCE; HALF LIFE TIME; HYPERTENSION; IMAGING SYSTEM; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; REDOX STRESS; RENAL ARTERY; RENAL PROTECTION;

EID: 55449105848     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1643     Document Type: Article

References (36)

1. Halliwell B, Gutteridge JMC: Measurement of reactive species, in: Halliwell B, Gutteridge JMC (eds): Free Radicals in Biology and Medicine, 4th ed. London, Oxford Science Publications, 2007, pp 268-270.
2. Dikalov S, Griendling KK, Harrison DG: Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007; 49: 717-727.
3. Godfraind T: Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 2005; 360: 2259-2272.
4. Yokoyama H, Lin Y, Itoh O, et al: EPR imaging for in vivo analysis of the half-life of a nitroxide radical in the hippocampus and cerebral cortex of rats after epileptic seizures. Free Radic Biol Med 1999; 27: 442-448.
5. Togashi H, Matsuo T, Shinzawa H, et al: Ex vivo measurement of tissue distribution of a nitroxide radical after intravenous injection and its in vivo imaging using a rapid scan ESR-CT system. Magn Reson Imaging 2000; 18: 151-156.
6. Miura Y, Ozawa T: Noninvasive study of radiation-induced oxidative damage using in vivo electron spin resonance. Free Radic Biol Med 2000; 28: 854-859.
7. Hirayama A, Yoh K, Nagase S, et al: EPR imaging of reducing activity in Nrf2 transcriptional factor-deficient mice. Free Radic Biol Med 2003; 34: 1236-1242.
8. Kuppusamy P, Li H, Hangovan G, et al: Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 2002; 62: 307-312.
9. Ueda A, Nagase S, Yokoyama H, et al: Identification by an EPR technique of decreased mitochondrial reducing activity in puromycin aminonucleoside-induced nephrosis. Free Radic Biol Med 2002; 33: 1082.
10. Utsumi H, Yamada K: In vivo electron spin resonance-computed tomography/nitroxyl probe technique for noninvasive analysis of oxidative injuries. Arch Biochem Biophys 2003; 416: 1-8.
11. Yamada K, Yamamiya I, Utsumi H: In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue. Free Radic Biol Med 2006; 40: 2040-2046.
12. Hirayama A, Nagase S, Ueda A, et al: In vivo imaging of oxidative stress in ischemia-reperfusion renal injury using electron paramagnetic resonance. Am J Physiol Renal Physiol 2005; 288: F597-F603.
13. Ueda A, Yokoyama H, Nagase S, et al: In vivo temporal FPR imaging for estimating the kinetics of a nitroxide radical in the renal parenchyma and pelvis in rats. Magn Reson Imaging 2002; 20: 77-82.
14. Matsui T, Yamagishi S, Nakamura K, Inoue H: Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res 2006; 34: 671-675.
15. Nakamura K, Yamagishi S, Inoue H: Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist. Med Hypotheses 2005; 65: 155-157.
16. Nakano K, Egashira K, Ohtani K, et al: Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice. Atherosclerosis 2008; 196: 172-179.
17. Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T: Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension 1997; 29: 1025-1030.
18. Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 2003; 108: 2034-2040.
19. Papaharalambus CA, Griendling KK: Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007; 17: 48-54.
20. Cifuentes ME, Pagano PJ: Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 179-186.
21. Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-1081.
22. Escobales N, Crespo MJ: Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 2005; 3: 231-246.
23. Mason RP, Walter MF, Trumbore MW, Olmstead EG Jr, Mason PE: Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31: 275-281.
24. Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W: Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240-245.
25. Spieker LE, Flammer AJ, Lüscher TF: The vascular endothelium in hypertension. Handb Exp Pharmacol 2006; 176 Pt2: 249-283.
26. Jinno T, Iwai M, Li Z, et al: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
27. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724-730.
28. Lee MC, Shoji H, Miyazaki H, et al: Assessment of oxidative stress in the spontaneously hypertensive rat brain using electron spin resonance (ESR) imaging and in vivo L-band ESR. Hypertens Res 2004; 27: 485-492.
29. Sano T, Umeda F, Hashimoto T, Nawata H, Utsumi H: Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 1998; 41: 1355-1360.
30. Han JY, Takeshita K, Utsumi H: Noninvasive detection of hydroxyl radical generation in lung by diesel exhaust particles. Free Radic Biol Med 2001; 30: 516-525.
31. Okajo A, Matsumoto K, Mitchell JB, Krishna MC, Endo K: Competition of nitroxyl contrast agents as an in vivo tissue redox probe: comparison of pharmacokinetics by the bile flow monitoring (BFM) and blood circulating monitoring (BCM) methods using X-band EPR and simulation of decay profiles. Magn Reson Med 2006; 56: 422-431.
32. Yamada K, Inoue D, Matsumoto S, Utsumi H: In vivo measurement of redox status in streptozotocin-induced diabetic rat using targeted nitroxyl probes. Antioxid Redox Signal 2004; 6: 605-611.
33. Fuchs J, Groth N, Herrling T, Zimmer G: Electron paramagnetic resonance studies on nitroxide radical 2,2,5,5-tetramethyl-4-piperidin-1-oxyl (TEMPO) redox reactions in human skin. Free Radic Biol Med 1997; 22: 967-976.
34. Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-1212.
35. Hirayama A, Yoh K, Ueda A, et al: Nrf2 deficiency intensifies early phase renal damage in streptozotocin-induced diabetic mice. Free Radic Biol Med 2004; 37: S134.
36. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857.